Purchase this article with an account.
Antoine Heitz, Sauer Arnaud, Carine Merklen, Bernard Cribier, Claude Speeg-Schatz, Tristan Bourcier; Oral azithromycin versus doxycyclin for the treatment of moderate to severe meibomian gland dysfunction (MGD): a randomized prospective non-inferiority study.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1481.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The main purpose of this study was to evaluate the clinical efficiency and safety of oral azithromycin versus oral doxycyclin in the treatment of subjects with moderate to severe MGD. We were also able to evaluate rosacea prevalence for the trial population.
Patients with moderate to severe MGD (n=95) were randomized to receive oral azithromycin 500 mg three times a week tapered for 3 months (n=49) or oral doxycyclin 100mg daily for 3 months (n=46). Primary outcome measures were palpebral signs and dermatologic signs of rosacea. Secondary measures were quality of life, Tear film Break Up Time, corneal staining, tolerance and compliance. Statistical analysis was performed using Mann-Whitney-Wilcoxon tests.
Azithromycin showed statistically significant non-inferiority for all endpoints as compared to doxycycline. Excellent tolerance was observed with only 5% percent occurrence of side effects in both groups. Compliance was good with 7% of non-compliant patients in both groups.
Oral azithromycin seems to be an excellent alternative to oral doxycyclin in patients with moderate to severe MGD.
This PDF is available to Subscribers Only